Comparison of conventional NSAIDs and cyclooxygenase-2 inhibitors in outpatients

Joint Bone Spine

Volumn 72, Issue 5, 2005, Pages 397-402

  Modica, Martine ^a   Vanhems, Philippe ^b   Tebib, Jacques ^c  

^a Pharmacien Conseil Au Service Médical de l'Assurance Maladie de l'Ain   (France)

^b INSERM   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

COX2 inhibitors; Cyclooxygenase 2 inhibitors; Nonsteroidal antiinflammatory drugs; NSAID

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; ANTITHROMBOCYTIC AGENT; CHONDROITIN; CYCLOOXYGENASE 2 INHIBITOR; DIACETYLRHEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DIURETIC AGENT; GOLD; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; DATA BASE; DRUG MARKETING; FEMALE; HEALTH INSURANCE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; OSTEOARTHRITIS; OUTPATIENT; PRESCRIPTION;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; CROSS-SECTIONAL STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DRUG UTILIZATION; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PHYSICIAN'S PRACTICE PATTERNS; PROFESSIONAL PRACTICE;

EID: 26244459194     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2005.05.002     Document Type: Article

References (35)

1. B. Terlain Efficacy and tolerance of NSAID: what future for COX 1 and 2 inhibitors? Therapie 54 1999 278 [Abstract]
2. C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, and B. Davis Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N. Engl. J. Med. 343 2000 1520 1528
3. F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, and A. Whelton Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: a randomised controlled trial JAMA 284 2000 1247 1255
4. Commission de la transparence. Vioxx® Avis du 3 avril 2002 http://afssaps.sante.fr.
5. Commission de la transparence. Vioxx® Avis du 16 juin 2004 http://www.afssaps.sante.fr.
6. Commission de la transparence. Celebrex® Avis du 16 juin 2004 http://www.afssaps.sante.fr.
7. R. Day, B. Morrison, A. Luza, O. Castaneda, A. Strusberg, and M. Nahir A randomized trial of the efficacy and tolerability of the cox-2 inhibitor rofecoxib versus ibuprofen in patients with osteoarthritis Arch. Intern. Med. 160 2000 1781 1787
8. J.J. Deeks, L.A. Smith, and M.D. Bradley Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials BMJ 325 2002 619 623
9. L. Simon, A. Weaver, D. Graham, A. Kivitz, P. Lipsky, and R. Hubbard Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial JAMA 282 1999 1921 1928
10. F. Berenbaum Anti-inflammatoires non st́roïdiens Rev. Prat. 53 2003 502 506
11. M.E. Farkouh, H. Kirshner, R.A. Harrington, S. Ruland, F.W. Verheugt, and T.J. Schnitzer Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial Lancet 364 2004 639 640
12. F. Berenbaum Ślective cyclooxygenase-2 inhibitors: hope and facts Joint Bone Spine 67 2000 499 501
13. Afssaps. Communiqué de presse «Réévaluation et nouvelles conditions d'emploi des coxibs» 1 juillet 2004 http:/afssaps.sante.fr.
14. es journées de pharmacovigilance Rennes avril 2002:: page 7 (abstract 034).
15. ®) Current Problems in Pharmacovigilance 26 2000 13
16. C.J. Harris, and D.C. Brater Renal effects of cyclooxygenase-2 selective inhibitors Curr. Opin. Nephrol. Hypertens. 10 2001 603 610
17. Department of Health and Human Services Public Health Service. Food and Drug Administration. Center for drug evaluation and research "OPDRA post-marketing safety review - ŕnal" Jan 7 2001 (18 pages)
18. R" 30 septembre 2004 http://afssaps.sante.fr.
19. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. http://www.nejm.org February 15, 2005.
20. Solomon SD, McMurray J, Pfeffer M, Wittes J, Fowler R, Finne P, et al. Cardiovascular risks associated with celecoxib in a clinical trial for colorectal adenoma prevention http://www.nejm.org February 15, 2005.
21. ® Le dictionnaire. 80̀me éd 2004 Vidal Issy-les-Moulineaux
22. o:53. La population protégée par les régimes de sé curité sociale au 31 décembre 2000 http://www.ameli.fr.
23. CNAMTS. MEDIC'AM, Les médicaments remboursés par le régime général d'assurance maladie au cours des années 2001 et 2002, juillet 2003 http://www.ameli.fr.
24. Référentiel national des interactions mé dicamenteuses http://afssaps.santé.fr/htm/10/iam/indiam.htm.
25. U. Haglund, and P. Svarvar The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis Rheumatol. 39 Suppl 2 2000 51 56
26. J. Pellissier, W. Straus, D. Watson, S. Kong, and S. Harper Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis Clin. Therap. 23 2001 1061 1079
27. S. Bouee, A. Charlemagne, F. Fagnani, P. Le Jeunne, C. Sermet, and F. Naudin Evolution du traitement de l'arthrose en ḿdecine ǵńrale apr̀s la mise sur le march́ des AINS anticox2 ślectifs et co-prescriptions de gastroprotecteurs Rev. Rhum. 71 2004 378 385
28. Bonenfant S, Chastang JF, Kaniewski N, Piccioti M, Zins M, Niedhammer I, et al. Principales données. Cohorte GAZEL des 20 000 volontaires: anńe 9 (1998). Juillet 1999. http://www.gazel.inserm.fr.
29. A. Cantagrel, and B. Mazìres Polyarthrite rhumatoïde: donńes ́pid́miologiques, devenir à long terme et coût de la prise en charge Rev. Rhum. 65 5 bis 1998 158S 160S
30. Anonyme. Direction Géńrale de la Santé, Rapport du Groupe Technique National de définition des objectifs, élaboration de la loi d'orientation de santé publique, 10 mars 2003. http://www.sante.gouv.fr/htm/dossiers/losp/index.htm.
31. C. Larousse, and G. Veyrac Les inhibiteurs de COX-1 et COX-2, donńes cliniques: quelles alertes possibles en pharmacovigilance Therapie 55 2000 21 28
32. F. Berenbaum NSAIDs and aspirin: friends or foes? Joint Bone Spine 70 2003 89 90
33. Afssaps Communiqué de presse "Sécurité d'emploi des coxibs: nouvelles contre-indications et mise en garde conceranant le risque cardio-vasculaire" 17 février 2005 http://www.afssaps.sante.fr.
34. F. Berenbaum Vioxx and cardiovascular events: a class effect? Joint Bone Spine 72 2005 1 3
35. Graham DJ, Campen DH, Cheetam C, Hui R, Spence M, Ray W, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygénase-2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Published online January 25, 2005 http://image.thelancet.com/extras/05art1005web.pdf.